InSphero will participate in a panel at the SITC EU Immuno-Oncology Drug Development Summit in Lausanne on September 3.
Public source
Publisher name
Public post
A human tumor spheroid with T cells added to it will tell you within 72 hours whether your molecule kills. It will not tell you whether the patient's immune system was e…
Company
InSphero
Reliable, reproducible, and scalable 3D in vitro platforms for drug safety & efficacy testing | The Model of Excellence™
- Industry
- Biotechnology Research
- Location
- Schlieren, CH
- Company size
- 51–200 employees
About InSphero
InSphero is the only 3D in vitro model company with the platform and expertise to modernize drug safety and efficacy testing in a way that empowers researchers to reach their full potential. Our innovative spheroid-based models allow for more effective and safe therapies to get to the clinic faster due to our superior robustness, reliability, reproducibility, and scalability. InSphero’s goal is to help researchers fuel a new era of drug discovery through comprehensive products and services for: - Liver safety - Liver disease - Islet Biology - Oncology & Immunology
See moreLatest activity
Latest activity from InSphero
10 signals
Presence & Recognition
InSphero is attending EUROTOX 2026 from September 13 to 16, highlighting applications across drug safety including collaborative work with Roche using InSphero 3D spheroids and high-throughput 3D organoid imaging in collaboration with Tecan.
Research & Knowledge
InSphero researchers Francisco Verdeguer and Joel Zvick contributed to a study published in The Journal of Clinical Investigation identifying EFHD1 as an important driver of hepatocyte injury in MASH.
Research & Knowledge
InSphero evaluated EFHD1 as a therapeutic target using its proprietary 3D InSight™ Human MASH model to assess disease-relevant features.
Discover more
Similar signals
Similar public activity from other companies.
Presence & Recognition
Precision For Medicine
Precision For Medicine is attending the SITC EU Immuno-Oncology Drug Development Summit 2026 in Lausanne.
Presence & Recognition
Mestag Therapeutics
Mestag Therapeutics CEO Susan Hill and CMO Lindsey Rolfe will attend the 2026 Society for Immunotherapy of Cancer (SITC) EU Immuno-Oncology Drug Development Summit in Lausanne, Switzerland, on September 3-4.
Presence & Recognition
Molecular Partners
Molecular Partners is hosting the 2026 Society for Immunotherapy of Cancer (SITC) EU Immuno-Oncology Drug Development Summit in Lausanne, Switzerland, from September 3 to 4.
Presence & Recognition
Applied Cells
Applied Cells is attending ISCT Asia 2026 in Singapore at the Summit 2 track on Wednesday, September 2, 2026, featuring Yuchen Zhou, Founder and CEO of Applied Cells discussing the Applied Cells GoFast™ CAR-T solution.
Presence & Recognition
RoukenBio